Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.52 |
| ▸ | RAB9A | P51151 | 5/20 | 0.52 |
| ▸ | CASP3 | P42574 | 2/20 | 0.52 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.52 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.42 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 5/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.42 |
| ▸ | F2 | P00734 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.41 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.41 |
| ▸ | BCL2 | P10415 | 1/20 | 0.40 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3096373 | 1.00 | NPC1 (0.52) | NPC1RAB9ACASP3SENP7SENP6 | |
| SCHEMBL3090637 | 0.92 | RAB9A (0.48) | RAB9AKDM4EMAPTENPP3ENPP1 | |
| SCHEMBL3102970 | 0.92 | MMP9 (0.46) | NPC1RAB9AKAT6AMEN1KMT2A | |
| SCHEMBL3093901 | 0.92 | MMP9 (0.46) | NPC1RAB9AKAT6AMEN1KMT2A | |
| SCHEMBL3092720 | 0.91 | MEN1 (0.53) | NPC1RAB9ACASP3SENP7SENP6 | |
| SCHEMBL3097645 | 0.90 | KAT6A (0.49) | NPC1RAB9ACASP3SENP7SENP6 | |
| SCHEMBL3093289 | 0.90 | KAT6A (0.49) | NPC1RAB9ACASP3SENP7SENP6 | |
| SCHEMBL3079467 | 0.90 | F2 (0.43) | NPC1RAB9AKDM4EKAT6AMAPT | |
| SCHEMBL3080048 | 0.89 | MEN1 (0.54) | NPC1RAB9ACASP3SENP7SENP6 | |
| SCHEMBL3093127 | 0.89 | GPR27 (0.48) | NPC1RAB9AKDM4EKAT6AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180280326-A1 | MEDICAMENT FOR PREVENTING OR INHIBITING ACUTE KIDNEY INJURY | NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER (JP) | 2018-10-04 | — | — | US | claimed |
| US-10071099-B2 | Medicament for suppressing malignant tumor metastasis | NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER (JP) | 2018-09-11 | — | — | US | claimed |
| EP-3127554-A1 | MEDICINE FOR SUPPRESSING MALIGNANT TUMOR METASTASIS | National Cerebral and Cardiovascular Center (JP) | 2017-02-08 | — | — | EP | claimed |
| US-20170014419-A1 | MEDICAMENT FOR SUPPRESSING MALIGNANT TUMOR METASTASIS | NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER (JP) | 2017-01-19 | — | — | US | claimed |
| EP-2172450-B9 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2014-10-08 | — | — | EP | claimed |
| EP-2172450-B1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-10-16 | — | — | EP | claimed |
| US-8461209-B2 | Malonic acid sulfonamide derivative and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-06-11 | — | — | US | claimed |
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-09-09 | — | — | US | claimed |
| EP-2172450-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-04-07 | — | — | EP | claimed |
| US-20180280326-A1 | MEDICAMENT FOR PREVENTING OR INHIBITING ACUTE KIDNEY INJURY | NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER (JP) | 2018-10-04 | — | — | US | disclosed |
| US-10071099-B2 | Medicament for suppressing malignant tumor metastasis | NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER (JP) | 2018-09-11 | — | — | US | disclosed |
| EP-3127554-A1 | MEDICINE FOR SUPPRESSING MALIGNANT TUMOR METASTASIS | National Cerebral and Cardiovascular Center (JP) | 2017-02-08 | — | — | EP | disclosed |
| US-20170014419-A1 | MEDICAMENT FOR SUPPRESSING MALIGNANT TUMOR METASTASIS | NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER (JP) | 2017-01-19 | — | — | US | disclosed |
| EP-2172450-B9 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2014-10-08 | — | — | EP | disclosed |
| EP-2172450-B1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-10-16 | — | — | EP | disclosed |
| US-8461209-B2 | Malonic acid sulfonamide derivative and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-06-11 | — | — | US | disclosed |
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-09-09 | — | — | US | disclosed |
| EP-2172450-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180280326-A1 | MEDICAMENT FOR PREVENTING OR INHIBITING ACUTE KIDNEY INJURY | AGTR2, AGTR1, REN | NPC1 2756/4885RAB9A 2218/4885CASP3 389/4885 |
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | REN, AGTR2, AGTR1 | NPC1 3306/4885RAB9A 826/4885CASP3 3474/4885 |
| US-20170014419-A1 | MEDICAMENT FOR SUPPRESSING MALIGNANT TUMOR METASTASIS | AGTR2, MME, AGTR1 | NPC1 2415/4885RAB9A 3461/4885CASP3 2026/4885 |
| US-10071099-B2 | Medicament for suppressing malignant tumor metastasis | AGTR2, MME, AGTR1 | NPC1 2415/4885RAB9A 3461/4885CASP3 2026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.